Quantcast

Latest Symphogen Stories

2014-02-25 23:36:32

Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody mixtures for the treatment of cancer. St. Louis, Missouri (PRWEB) February 25, 2014 Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing agreement with Symphogen, A/S...

2014-01-14 16:25:04

COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its achievements in 2013 and outlook for 2014 at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, California. The presentation was made by Kirsten Drejer, CEO. Pipeline update Symphogen has continued to expand its oncology pipeline to include projects that...

2014-01-14 12:26:37

PASADENA, Calif., Jan. 14, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing antibody-based products, today announced the appointment of inaugural members of its newly-formed scientific advisory board. The board will leverage its extensive experience in protein engineering to advise the company to help advance its proprietary monoclonal antibody (mAb) technology platform for the development of novel antibody-drug conjugates. "We are very proud to appoint...

2008-07-17 12:01:18

Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients. Up to 55 RhD-positive adult non-splenectomized patients with idiopathic thrombocytopenic purpura (ITP) will be enrolled in this first exploratory open label safety, efficacy and dose-finding trial. The study objective is to evaluate the...

2008-07-16 09:01:20

COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008. Symphogen A/S and Biovitrum AB (publ) (STO: BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic Thrombocytopenic Purpura (ITP) patients. Sym001 is a recombinant, polyclonal anti-Rhesus D antibody product candidate. Symphogen and Biovitrum are jointly developing Sym001 under a...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.